At AI Therapeutics, we are focused on identifying and developing therapeutics for rare orphan conditions. We accelerate the development process by using a variety of methods to identify and acquire promising pipeline assets - including data mining, deep learning, and in-licensing. Our current clinical stage drug candidates target several orphan disorders including pulmonary sarcoidosis, bronchiolitis obliterans post lung transplant and amyotrophic lateral sclerosis.